Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
Table 2
Multivariate analysis for factors associated with glycemic target achievement (HbA1c < 7.0%) following vildagliptin treatment.
Variable
Coefficient
SE of coefficient
value
value
Odds ratio
95% CI
Gender
0.06
0.14
0.21
0.645
1.07
0.81–1.41
Age
0.01
0.01
2.84
0.092
1.01
1.00-1.02
Weight
0.00
0.01
0.15
0.697
1.00
0.99–1.02
Concurrent disease
−0.25
0.23
1.13
0.288
0.78
0.49–1.24
Medical history
0.07
0.20
0.11
0.736
1.07
0.72–1.59
Concomitant medications (except for diabetes medications)
0.36
0.24
2.29
0.131
1.43
0.90–2.28
Duration of diabetes (1 year)
−0.08
0.01
52.72
<0.001
0.92
0.90–0.94
HbA1c < 7.5%
2.12
0.14
237.15
<0.001
8.30
6.34–10.86
Fixed dose combination treatment
0.50
0.19
6.58
0.010
1.65
1.13–2.41
SE: standard error; CI: confidence interval. Odds ratio of vidagliptin/metformin fixed dose combination was calculated in comparison with the free drug combination.
